BFEC
ABBV icon

Benjamin F. Edwards & Company’s AbbVie ABBV Stock Holding History

Benjamin F. Edwards & Company’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$47.7M Buy
278,306
+5,870
+2% +$972K 0.84% 18
2024
Q1 		$49.6M Buy
272,436
+8,972
+3% +$1.55M 0.9% 17
2023
Q4 		$40.8M Buy
263,464
+194,649
+283% +$28.4M 0.82% 21
2023
Q3 		$10.3M Sell
68,815
-3,069
-4% -$451K 0.39% 58
2023
Q2 		$9.69M Sell
71,884
-5,717
-7% -$838K 0.37% 61
2023
Q1 		$12.4M Buy
77,601
+4,926
+7% +$753K 0.52% 38
2022
Q4 		$11.7M Buy
72,675
+312
+0.4% +$47.8K 0.53% 40
2022
Q3 		$9.71M Buy
72,363
+26,797
+59% +$3.85M 0.49% 49
2022
Q2 		$6.98M Buy
45,566
+747
+2% +$114K 0.34% 72
2022
Q1 		$7.27M Buy
44,819
+648
+1% +$94.1K 0.32% 79
2021
Q4 		$5.98M Buy
44,171
+1,266
+3% +$150K 0.27% 84
2021
Q3 		$4.63M Sell
42,905
-1,215
-3% -$139K 0.23% 98
2021
Q2 		$4.97M Buy
44,120
+1,488
+3% +$168K 0.25% 94
2021
Q1 		$4.61M Sell
42,632
-52
-0.1% -$5.56K 0.25% 93
2020
Q4 		$4.57M Buy
42,684
+2,743
+7% +$264K 0.27% 86
2020
Q3 		$3.5M Buy
39,941
+1,777
+5% +$167K 0.23% 105
2020
Q2 		$3.75M Buy
38,164
+4,035
+12% +$355K 0.27% 85
2020
Q1 		$2.6M Sell
34,129
-2,206
-6% -$188K 0.22% 111
2019
Q4 		$3.22M Sell
36,335
-356
-1% -$29.6K 0.23% 112
2019
Q3 		$2.78M Sell
36,691
-2,228
-6% -$153K 0.22% 117
2019
Q2 		$2.83M Buy
38,919
+9,721
+33% +$764K 0.24% 101
2019
Q1 		$2.35M Buy
29,198
+9,259
+46% +$757K 0.21% 117
2018
Q4 		$1.84M Sell
19,939
-3,573
-15% -$314K 0.19% 127
2018
Q3 		$2.22M Sell
23,512
-10,897
-32% -$1.03M 0.21% 114
2018
Q2 		$3.19M Sell
34,409
-5,824
-14% -$569K 0.31% 77
2018
Q1 		$3.81M Buy
40,233
+6,556
+19% +$720K 0.39% 60
2017
Q4 		$3.26M Sell
33,677
-686
-2% -$64.7K 0.34% 72
2017
Q3 		$3.05M Buy
34,363
+12,765
+59% +$972K 0.37% 65
2017
Q2 		$1.57M Buy
21,598
+6,800
+46% +$457K 0.2% 111
2017
Q1 		$964K Buy
14,798
+1,925
+15% +$121K 0.14% 155
2016
Q4 		$806K Buy
12,873
+3,988
+45% +$243K 0.13% 171
2016
Q3 		$560K Sell
8,885
-322
-3% -$20.8K 0.1% 213
2016
Q2 		$570K Buy
9,207
+411
+5% +$25K 0.11% 192
2016
Q1 		$502K Buy
8,796
+678
+8% +$37.8K 0.1% 197
2015
Q4 		$481K Sell
8,118
-125
-2% -$7.2K 0.1% 192
2015
Q3 		$449K Buy
8,243
+85
+1% +$5.53K 0.1% 198
2015
Q2 		$548K Buy
8,158
+621
+8% +$40.5K 0.11% 192
2015
Q1 		$441K Buy
7,537
+1,806
+32% +$109K 0.09% 208
2014
Q4 		$375K Buy
5,731
+735
+15% +$46.3K 0.09% 218
2014
Q3 		$289K Hold
4,996
– – 0.07% 255
2014
Q2 		$282K Sell
4,996
-715
-13% -$37.5K 0.07% 248
2014
Q1 		$294K Buy
5,711
+395
+7% +$20K 0.08% 222
2013
Q4 		$281K Sell
5,316
-197
-4% -$9.68K 0.09% 204
2013
Q3 		$247K Buy
5,513
+1,037
+23% +$46K 0.09% 204
2013
Q2 		$185K Buy
+4,476
New +$196K 0.07% 221

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Benjamin F. Edwards & Company's ABBV Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its AbbVie (ABBV) stake by 2.2% in Q2 2024, buying an estimated $972K and bringing the position to 278,306 shares worth $47.7M. The position accounts for 0.84% of the portfolio, ranked #18.

Benjamin F. Edwards & Company first reported a position in ABBV in Q2 2013 and has held it in 45 quarters since. The position peaked at $49.6M in Q1 2024. 3,365 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

  • Benjamin F. Edwards & Company held 278,306 shares of AbbVie worth $47.7M as of Q2 2024.
  • Benjamin F. Edwards & Company bought 5,870 AbbVie shares in Q2 2024, an estimated $972K.
  • AbbVie made up 0.84% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #18 holding.
  • Benjamin F. Edwards & Company first reported a position in AbbVie in Q2 2013 and has held it in 45 quarters since.
  • Benjamin F. Edwards & Company's AbbVie position peaked at $49.6M in Q1 2024.
  • 3,365 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.